Results 31 to 40 of about 63,602 (218)

Cost effectiveness of treatments for wet age-related macular degeneration [PDF]

open access: yes, 2011
Age-related macular degeneration (AMD) is a leading cause of blindness in people aged >= 50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems.
Annemans, Lieven   +4 more
core   +1 more source

Evidence for more cost-effective surveillance options for bovine spongiform encephalopathy (bse) and scrapie in Great Britain [PDF]

open access: yes, 2017
Transmissible spongiform encephalopathies (TSEs) are an important public health concern. Since the emergence of bovine spongiform encephalopathy (BSE) during the 1980s and its link with human Creutzfeldt- Jakob disease, active surveillance has been a key
Arnold   +16 more
core   +3 more sources

Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma [PDF]

open access: yes, 2019
Background and Purpose: Glioblastomas are the most aggressive of all gliomas. The prognosis of these gliomas, which are classified as grade IV tumors by the World Health Organization (WHO), is poor.
Baguet, Tristan   +3 more
core   +1 more source

Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. [PDF]

open access: yes, 2013
Objectives To estimate the cost-effectiveness of remote monitoring strategies versus usual care for adults recently discharged after a heart failure (HF) exacerbation.
Al-Mohammad, A   +11 more
core   +1 more source

Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand [PDF]

open access: yes, 2015
Objectives. Haemophilia A is a congenital disorder of coagulation that mainly affects males and causes a considerable use of resources, especially when hemophilic patients are treated with prophylaxis.
BOCCIA, Antonio   +4 more
core   +2 more sources

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

open access: yes, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group   +47 more
core   +1 more source

Rethinking plastic waste: innovations in enzymatic breakdown of oil‐based polyesters and bioplastics

open access: yesFEBS Open Bio, EarlyView.
Plastic pollution remains a critical environmental challenge, and current mechanical and chemical recycling methods are insufficient to achieve a fully circular economy. This review highlights recent breakthroughs in the enzymatic depolymerization of both oil‐derived polyesters and bioplastics, including high‐throughput protein engineering, de novo ...
Elena Rosini   +2 more
wiley   +1 more source

Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure : analysis of the British NHS Bridge to Transplant (BTT) program [PDF]

open access: yes, 2001
Background: A previous cost-effectiveness analysis showed that bridge to transplant (BTT) with early design left ventricular assist devices (LVADs) for advanced heart failure was more expensive than medical management while appearing less beneficial ...
Aileen Clarke   +33 more
core   +9 more sources

Cost-effectiveness of a potential Zika vaccine candidate: a case study for Colombia [PDF]

open access: yes, 2018
Background: A number of Zika vaccine platforms are currently being investigated, some of which have entered clinical trials. We sought to evaluate the cost-effectiveness of a potential Zika vaccine candidate under the WHO Vaccine Target Product Profile ...
Moghadas, Seyed   +2 more
core   +2 more sources

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy